Tagged with R&D

Pharma Family-owned Laboratori Baldacci is something of a rare breed in an industry dominated by multinational players. The senior research manager discusses the history of the company as well as how it plans to leverage its portfolio of innovative products and internationalization to drive growth in future. Could you please provide…

Pharma The Director-General of the Gustave Roussy Institute, a top cancer institute in Europe, talks about the revamping of their clinical research infrastructure to adapt to the rising new field of translational research and his ambitious plans for the next five years, in particular, his vision for Cancer Core Europe, positioned…

Pharma Yann Quentric has assumed new responsibilities as president of Iris Pharma; leading the first CRO to specialize exclusively in ophthalmology. From the company’s humble beginnings in southern France to its current international reach, Mr. Quentric shares his vision on the next chapter for the company. Can you start by introducing Iris Pharma…

Pharma Laurent Levy, CEO at Nanobiotix, is leading the way in nanomedicine with new market-disruptive developments, establishing a growing presence in European and global research labs and pushing back the frontiers in healthcare, for the industry and for patients. What is the main focus of your work at Nanobiotix, a company you co-founded 12 years ago,…

Pharma Boasting a more than 14 percent growth rate in 2015, AbbVie has cemented its status as a top 20 pharmaceutical company in France. Sharing the unique relationship the company has with France, general manager Jerome Bouyer offers an optimistic view of how the French healthcare sector can best be structured…

Pharma Elena Tremoli, Scientific Director at Centro Cardiologico Monzino, explains the importance of both applied and cardiovascular research in Italy, and how prevention in this area will be key in the future. Centro Cardiologico Monzino is the only institute of excellence in Europe exclusively devoted to cardiovascular diseases. Can you describe…

Pharma Pharmaceuticals Mauritius’s economic stability, genetic diversity, cost competitiveness, and location make it a perfect location for clinical research; a fact the state is now actively promoting. A further vision of the Mauritian government is to transform the island into a medical hub for clinical research. Besides political and economic stability, a number of…

Pharma Pharmaceuticals Eugenio Aringhieri discusses Dompé’s shift in strategy towards opthalmology, instilling an innovation mindset, and broadening the company’s international horizons. Since we last interviewed you in 2009 a lot has happened: you were made European CEO in 2015 for having steered Dompé through considerable renewal and restructuring, the company also embarked…

Pharma Olivier Laureau, President of the Servier Group, discusses how Servier´s economic model is based on considerable investments in R&D to provide for a better future and on a strong international footprint; and how their ambition is to grow from total revenues of 4 billion euros (4.46 billion USD) today, to…

Pharma Galderma Italy was a founding European affiliate for the company and has seen incredible growth in the past two decades. Managing Director  Bernat Albinyana discusses the affiliate’s performance, its business organization and commitment to R&D, as well as its grand ambitions for the next few years. In 1986, Italy was…

Pharma The chairman of Egypt’s largest holding company for pharmaceutical manufacturers, ACDIMA, shares his vision for how Egyptian manufacturers can enhance their competitiveness in the coming years, and extend their activities further up the value chain into API production and R&D activities. How well prepared are Egyptian companies to compete in…

Pharma Puerto Rico is starting to move towards greater R&D activity. World class research centers in cardiovascular, oncology, and soon molecular science are putting the territory on the global map for pharmaceutical research. But Puerto Rico is starting to move beyond manufacturing and towards greater R&D activity. Puerto Rico’s Cardiovascular and…